Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$26.77 USD
+0.04 (0.15%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $26.76 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Brokerage Reports
0 items in cart
[RPRX]
Reports for Purchase
Showing records 41 - 55 ( 55 total )
Industry: Medical - Biomedical and Genetics
Shares Oversold While Androxal Fundamentals Remain Intact
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Renewed Comfort on the Success of Androxal in Secondary Hypogonadism
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Positive Proellex in UF Phase II Results Should Advance Phase III Studies
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
The Second Time Could Be the Char-We are initiating coverage
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Industry: Medical - Biomedical and Genetics
IND for an Androxal Phase II Study OK?d by FDA; Study Design Not Finalized; Additional Capital Needed Prior to Initiation of Study.
Provider: WEDBUSH SECURITIES INC.
Analyst: LEE K